UNRESECTABLE RENAL CELL CARCINOMA
Clinical trials for UNRESECTABLE RENAL CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE RENAL CELL CARCINOMA trials appear
Sign up with your email to follow new studies for UNRESECTABLE RENAL CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Gut bacteria boost may help kidney cancer drugs work better
Disease control OngoingThis early-phase study looks at whether adding a probiotic called CBM588 to the usual two-drug treatment (cabozantinib and nivolumab) can improve outcomes for people with advanced kidney cancer that has spread. The probiotic is meant to increase helpful gut bacteria, which may he…
Matched conditions: UNRESECTABLE RENAL CELL CARCINOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 26, 2026 04:11 UTC
-
Personalized cell therapy trial for advanced cancers withdrawn before enrollment
Disease control TerminatedThis early-stage trial aimed to test the safety and effectiveness of STIL101, a personalized cell therapy made from a patient's own tumor-fighting T cells, for several advanced cancers including pancreatic, colorectal, kidney, cervical, and melanoma. The treatment involved collec…
Matched conditions: UNRESECTABLE RENAL CELL CARCINOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
New combo therapy shows promise for rare kidney cancer
Disease control OngoingThis study tests whether combining two drugs—axitinib (which blocks cancer cell growth) and nivolumab (which helps the immune system attack cancer)—works better than nivolumab alone for a rare type of kidney cancer called TFE/translocation renal cell carcinoma (tRCC). The trial i…
Matched conditions: UNRESECTABLE RENAL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
Fasting to fight cancer: new study tests eating windows for better immunotherapy results
Knowledge-focused TerminatedThis study was designed to see if limiting eating to a 10-hour window each day could help immunotherapy work better in people with advanced head and neck or kidney cancer. Researchers planned to compare outcomes in African American participants and others. The study was withdrawn…
Matched conditions: UNRESECTABLE RENAL CELL CARCINOMA
Phase: NA • Sponsor: Duke University • Aim: Knowledge-focused
Last updated May 26, 2026 03:57 UTC